Announcements Trials
Browse Landscape

Phase

Phase 2 34Phase 1/2 25Phase 1 22Phase NA 7Phase EARLY_PHASE1 3Phase 3 3Phase 4 2Phase 2/3 1

Status

Completed 78Active not recruiting 24Terminated 20Unknown 16Recruiting 15Withdrawn 3Not yet recruiting 2

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Dermatologic 3

Conditions

Breast Neoplasms 25Neoplasms 19Prostatic Neoplasms 15Carcinoma, Non-Small-Cell Lung 15Carcinoma, Hepatocellular 10Urinary Bladder Neoplasms 8Ovarian Neoplasms 8Head and Neck Neoplasms 8Pain 7Lung Neoplasms 7Leukemia, Myeloid, Acute 7Squamous Cell Carcinoma of Head and Neck 6Neoplasm Metastasis 6Lymphoma, Follicular 6Leukemia 6Uterine Cervical Neoplasms 5Stomach Neoplasms 5Recurrence 5Precursor Cell Lymphoblastic Leukemia-Lymphoma 5Non-Muscle Invasive Bladder Neoplasms 5Brain Neoplasms 5Small Cell Lung Carcinoma 4Multiple Myeloma 4Lymphoma, Non-Hodgkin 4Lymphoma 4Leiomyoma 4Carcinoma 4Urologic Neoplasms 3Urogenital Neoplasms 3Papillomavirus Infections 3

Interventions

sargramostim 1cobimetinib 1Vemurafenib 1Sentinel Lymph Node Biopsy 1Saline Solution, Hypertonic 1Interferon-alpha 1Granulocyte-Macrophage Colony-Stimulating Factor 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 3 × Withdrawn × Melanoma × Clear all
NCT01826864 2020-07-27

Sargramostim or Hypertonic Saline Before Sentinel Lymph Node Biopsy in Treating Patients With Stage IB-II Melanoma

Jonsson Comprehensive Cancer Center

Phase 3 Withdrawn
Dermatologic

Melanoma

NCT02427893 2016-11-15

Trial of Vemurafenib and Cobimetinib in Patients With Advanced BRAFV600 Mutant Melanoma

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 3 Withdrawn
Dermatologic

Melanoma

NCT00447356 2013-05-13

High-Dose Interferon Alfa in Treating Patients With Stage II or StageIII Melanoma

Hackensack Meridian Health

Phase 3 Withdrawn
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡